⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 7, 2024Clinical Psychopharmacology and NeuroscienceOpen Access

A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis

Masakazu Hatano Haruna Araki Takeo Saito Shigeki Yamada

View Full Paper

Ask AI

Bookmark

Share

Abstract

This pharmacovigilance study evaluated the profile of clozapine-related adverse events by region using the Food and Drug Administration Adverse Event Reporting System (FAERS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hatano et al. (2024) studied this question.

synapsesocial.com/papers/68e65aacb6db6435875e8ed0 https://doi.org/10.9758/cpn.24.1174

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database2024 · 3 citations
2Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 20162024 · 10 citations
3Analysis of Adverse Drug Reactions of Clofazimine Reported in the FDA Adverse Event Reporting System from 2004 to 2025 Q12025
4Clozapine Efficacy and Adverse Drug Reactions Among a Nationwide Study of 1021 Australians Prescribed Clozapine: The ClozaGene Study2024 · 15 citations
5Compatitive pharmacovigilance study of clozapine and it's safer substitutes in schizophrenia managementReview · 2026